Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy

Expert Opinion on Biological Therapy

Volumn 12, Issue SUPPL. 1, 2012, Pages

  Stoetzer, Oliver J ^a   Wittwer, Christin ^b   Lehner, Julia ^b   Fahmueller, Yvonne N ^b   Kohles, Nikolaus ^b   Fersching, Debora Mi ^b   Leszinski, Gloria ^b   Roessner, Juliane ^b   Holdenrieder, Stefan ^b,c  

^a Haematology/Oncology Outpatient Specialty Center   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Biomarkers; Cancer; Chemotherapy; DNAse; HMGB1; Immunogenic cell death; Nucleosomes; Prediction; Prognosis; RAGE; Serum; SIRT; TACE

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTINEOPLASTIC AGENT; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CD24 ANTIGEN; CYTOKERATIN 19 FRAGMENT; CYTOTOXIC AGENT; DEOXYRIBONUCLEASE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1; LACTATE DEHYDROGENASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANTIGEN PRESENTING CELL; APOPTOSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CHEMOEMBOLIZATION; COLORECTAL CANCER; CONFERENCE PAPER; DENDRITIC CELL; DNA BINDING; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; MACROPHAGE; NEOPLASM; NONSURGICAL INVASIVE THERAPY; NUCLEOSOME; PANCREAS CANCER; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOEMBOLIZATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; NEOPLASMS; NUCLEOSOMES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861442190     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.689280     Document Type: Conference Paper

References (57)

1. Available from:; . http://www.nccn.org/professionals/physician-gls/f- guidelines.asp
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer 2009;45:228-47
3. Beachy SH, Repasky EA. Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 2008;57:759-75
4. Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 2012;35:745-63
5. D'Ippolito G, Torres LR, Saito Filho CF, et al. CT and MRI in monitoring response: state-of-the-art and future developments. Q J Nucl Med Mol Imaging 2011;55:603-19
6. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92
7. Sturgeon CM, DuffyMJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79 (Pubitemid 352777353)
8. Stieber P, Holdenrieder S. Lung cancer biomarkers - where we are and what we need. Cancer Biomark 2010;6:221-4
9. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-99
10. Holdenrieder S, Nagel D, Schalhorn A, et al. Clinical relevance of circulating nucleosomes in cancer. disease. Ann NY Acad Sci 2008;1137:180-9
11. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit Rev Lab Med Sci 2009;46:1-24
12. Holdenrieder S, Stief J, Bergner A, et al. Nucleosomes indicate the in vitro radiosensitivity of irradiated broncho-epithelial and lung cancer cells. Tumor Biol 2004;25:321-6 (Pubitemid 40082337)
13. Kumar S, Guleria R, Singh V, et al. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010;11:36-44
14. Holdenrieder S, Stieber P, v Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non small cell lung cancer. Clin Cancer Res 2004;10:5981-7 (Pubitemid 39287502)
15. Holdenrieder S, Stieber P, v Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann NY Acad Sci 2006;1075:244-75
16. Holdenrieder S, v Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1 and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008;14:7813-21
17. Holdenrieder S, v Pawel J, Dankelmann E, et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009;63:128-35
18. Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol 2005;26:44-9 (Pubitemid 40529297)
19. Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol 2006;27:235-42 (Pubitemid 44260248)
20. Mueller S, Holdenrieder S, Stieber P, et al. Early prediction of therapy response in patients with acute myeloid leukaemia by nucleosomal DNA fragments. BMC Cancer 2006;6:143
21. Zeerleder S, Zwart B, Wuillemin WA, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003;31:1947-51 (Pubitemid 36900748)
22. Lo YM, Rainer TH, Chan LYS, et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-23 (Pubitemid 30152256)
23. Geiger S, Holdenrieder S, Stieber P, et al. Nucleosomes in serum of patients with early cerebral stroke. Cerebro Vasc Dis 2006;21:32-7 (Pubitemid 43110307)
24. Holdenrieder S, Eichhorn P, Beuers U, et al. Nucleosomal DNA fragments in autoimmune diseases. Ann NY Acad Sci 2006;1075:318-27 (Pubitemid 44532800)
25. Koutouzov S, Jeronimo AL, Campos H, et al. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004;30:529-58 (Pubitemid 38917000)
26. Sallai K, Nagy E, Derfalvy B, et al. Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol 2005;12:56-9
27. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Different 2008;15:3-12 (Pubitemid 350286167)
28. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8::59-73
29. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61-9
30. Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28:367-88
31. Bianchi ME. HMGB1 loves company. J Leukocyte Biol 2009;86:573-6
32. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008;205:3007-18
33. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42 (Pubitemid 40516158)
34. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9 (Pubitemid 47517504)
35. Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008;68:4026-30
36. Chung HW, Lee SG, Kim H, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009;7:38
37. Naumnik W, Nilklinska W, Ossolinska M, et al. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol 2009;47:703-9
38. Tang DL, Kang R, Zeh HJ, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta Gene Regul Mech 2010;1799:131-40
39. Kang R, Tang D, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010;17:666-76
40. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologica 2009;52:2251-63
41. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in cancer and inflammation. J Translat Med 2010;7:17
42. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006;13:1971-8
43. Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. N Engl J Med 2012;366:1156-8
44. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7
45. Tang D, Kang R, Cheh CW, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010;29:5299-310
46. Liu R, Gong J, Chen J, et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother 2011;published online; DOI: 10.1007/ s00262-011-1146-8
47. Shang GH, Jia CQ, Tian H, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009;103:1949-53
48. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008;40:446-52
49. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CAFRA 21-1, and CEA levels.. Croat Med J 2009;50:455-64
50. Goldstein RS, Gallowitsch-Puerta M, Yang L, et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006;25:571-4 (Pubitemid 44297016)
51. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005;33:564-73 (Pubitemid 40365558)
52. Fahmueller Y, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing selective internal radiation therapy. BMC Cancer 2012;12:5
53. Fahmueller Y, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE and DNAse indicate response to radioembolisation therapy in colorectal cancer patients. Int J Cancer 2012; accepted
54. Wittwer C, Lehner J, Fersching D, et al. Methodical validation of an immunoassay for the determination of soluble receptors of advanced glycation end products (sRAGE). Anticancer Res 2012; In press
55. Lehner J, Wittwer C, Fersching D, et al. Methodical validation of an immunoassay for the determination of soluble high mobility group box 1 (sHMGB1). Anticancer Res 2012; In press
56. Fehr Y, Holdenrieder S, Hoffmann RT, et al. Circulating nucleosomes in cancer patients with liver metastases undergoing selective internal radiation therapy using Yttrium-90 labelled microspheres. In: Gahan P, editors. Circulating nucleic acids in plasma and serum. Springer, New York/ Heidelberg 2011. p. 91-5
57. Kohles N, Nagel D, Jungst D, et al. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer, 2011;11:202